For people with cystic fibrosis, like Sabrina Walker, Trikafta has been a life-changer. Before she started taking the drug, she would wind up in the hospital for weeks at a time until antibiotics could eliminate the infections in her lungs. Every day, she would wear a vest that shook her body to loosen the mucus […]
A state board charged with addressing the affordability of the most expensive prescription drugs has chosen Trikafta among its first five drugs to review, and it could move to cut the medication’s average in-state annual price of approximately $200,000.
The Colorado board’s choice of drugs to review elucidates one of the thorniest questions it must wrangle with: Would lowering the price tag for rare-disease medications lead manufacturers to pull out of the state or limit their availability?